BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Home » Topics » Briefs » In the clinic

In the clinic
In the clinic RSS Feed RSS

In the clinic for Sept. 6, 2024

Sep. 6, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Crestone, Cyclo, Eli Lilly, Indaptus, Pleopharma, Poseida.
Read More

In the clinic for Sept. 5, 2024

Sep. 5, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aelis, Athira, Biogen, Genentech, Jnana, Telix, Tris, Vesper.
Read More

In the clinic for September 5, 2024

Sep. 5, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Ciliatec.
Read More

In the clinic for Sept. 4, 2024

Sep. 4, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Anthos, Alnylam, Arrowhead, Avadel, Bayer, Bridgebio, Bristol Myers, Cogent, Cytokinetics, Dyne, Elysium, George Medicines, Imugene, IO Biotech, Lexicon, NH Theraguix, Novo Nordisk, Nucana, Praxis Precision Medicines, Prokidney, Recursion, Redhill Biopharma, Regenxbio, Remedy Pharmaceuticals, Sanofi, Valneva, Vaxcyte.
Read More

In the clinic for September 4, 2024

Sep. 4, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Edwards, Elixir, Histosonics.
Read More

In the clinic for September 3, 2024

Sep. 3, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Lunit.
Read More

In the clinic for August 30, 2024

Aug. 30, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Grail, Kiyatec, Median Technologies.
Read More

In the clinic for Aug. 30, 2024

Aug. 30, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Gain Therapeutics, Merck.
Read More

In the clinic for Aug. 29, 2024

Aug. 29, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Arcutis, Krystal, Neurocrine, Novartis, Nxera, Shilpa Medicare.
Read More

In the clinic for August 29, 2024

Aug. 29, 2024
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Klick, Polarisar, Sonde Health.
Read More
Previous 1 2 … 73 74 75 76 77 78 79 80 81 … 322 323 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 5, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing